6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
are	VBP	are	are	are	N	O
described	VBN	described	described	describ	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
.	.	.	.	.	N	O

Hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
Decompensation	NNP	decompensation	decompensation	decompens	N	I-AdverseReaction
in	IN	in	in	in	N	O
Patients	NNP	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Chronic	NNP	chronic	chronic	chronic	N	O
Hepatitis	NNP	hepatitis	hepatitis	hepat	Y	O
C	NNP	c	c	c	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O

Hepatotoxicity	NNP	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O

Thrombotic	JJ	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
Thromboembolic	NNP	thromboembolic	thromboembolic	thromboembol	N	B-AdverseReaction
Complications	NNP	complications	complication	complic	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O

Cataracts	NNS	cataracts	cataract	cataract	Y	B-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)]	NN	)]	)]	)]	N	O

In	IN	in	in	in	N	O
adult	NN	adult	adult	adult	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
ITP	NNP	itp	itp	itp	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
5%	CD	5%	5%	5%	N	O
and	CC	and	and	and	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
:	:	:	:	:	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
increased	JJ	increased	increased	increas	N	B-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
,	,	,	,	,	N	O
myalgia	NN	myalgia	myalgia	myalgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

In	IN	in	in	in	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
age	NN	age	age	age	N	O
6	CD	6	6	6	N	O
years	NNS	years	year	year	N	O
and	CC	and	and	and	N	O
older	JJR	older	older	older	N	O
with	IN	with	with	with	N	O
ITP	NNP	itp	itp	itp	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
10%	CD	10%	10%	10%	N	O
and	CC	and	and	and	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
rhinitis	NN	rhinitis	rhinitis	rhiniti	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
chronic	JJ	chronic	chronic	chronic	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
C	NNP	c	c	c	N	O
-	:	-	-	-	N	O
associated	VBN	associated	associated	associ	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
10%	CD	10%	10%	10%	N	O
and	CC	and	and	and	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
:	:	:	:	:	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	NN	appetite	appetite	appetit	N	I-AdverseReaction
,	,	,	,	,	N	O
influenza	JJ	influenza	influenza	influenza	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
like	IN	like	like	like	N	I-AdverseReaction
illness	NN	illness	illness	ill	N	I-AdverseReaction
,	,	,	,	,	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
insomnia	NN	insomnia	insomnia	insomnia	Y	B-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
,	,	,	,	,	N	O
chills	NNS	chills	chill	chill	Y	B-AdverseReaction
,	,	,	,	,	N	O
myalgia	NN	myalgia	myalgia	myalgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
alopecia	NN	alopecia	alopecia	alopecia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
aplastic	JJ	aplastic	aplastic	aplast	N	O
anemia	NN	anemia	anemia	anemia	Y	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
:	:	:	:	:	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
GlaxoSmithKline	NNP	glaxosmithkline	glaxosmithkline	glaxosmithklin	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
888	CD	888	888	888	N	O
-	:	-	-	-	N	O
825	CD	825	825	825	N	O
-	:	-	-	-	N	O
5249	CD	5249	5249	5249	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O

Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

Chronic	NNP	chronic	chronic	chronic	N	O
Immune	NNP	immune	immune	immun	N	O
(	(	(	(	(	N	O
Idiopathic	NNP	idiopathic	idiopathic	idiopath	N	O
)	)	)	)	)	N	O
Thrombocytopenia	NNP	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	O
:	:	:	:	:	N	O
Adults	NNS	adults	adult	adult	N	O
:	:	:	:	:	N	O
In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
and	CC	and	and	and	N	O
most	JJS	most	most	most	N	O
hemorrhagic	JJ	hemorrhagic	hemorrhagic	hemorrhag	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
followed	VBD	followed	followed	follow	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
included	VBD	included	included	includ	N	O
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	B-AdverseReaction
complications	NNS	complications	complication	complic	N	I-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
described	VBD	described	described	describ	N	O
below	IN	below	below	below	N	O
reflect	JJ	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
of	IN	of	of	of	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
to	TO	to	to	to	N	O
446	CD	446	446	446	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
chronic	JJ	chronic	chronic	chronic	N	O
ITP	NNP	itp	itp	itp	N	O
aged	VBD	aged	aged	age	N	O
18	CD	18	18	18	N	O
to	TO	to	to	to	N	O
85	CD	85	85	85	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
whom	WP	whom	whom	whom	N	O
65%	CD	65%	65%	65%	N	O
were	VBD	were	were	were	N	O
female	JJ	female	female	femal	N	O
,	,	,	,	,	N	O
across	IN	across	across	across	N	O
the	DT	the	the	the	N	O
ITP	NNP	itp	itp	itp	N	O
clinical	JJ	clinical	clinical	clinic	N	O
development	NN	development	development	develop	N	O
program	NN	program	program	program	N	O
including	VBG	including	including	includ	N	O
three	CD	three	three	three	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

PROMACTA	NNP	promacta	promacta	promacta	N	O
was	VBD	was	wa	wa	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
277	CD	277	277	277	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
and	CC	and	and	and	N	O
202	CD	202	202	202	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1	CD	1	1	1	N	O
year	NN	year	year	year	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
presents	VBZ	presents	present	present	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
experienced	VBN	experienced	experienced	experienc	N	O
by	IN	by	by	by	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
)	)	)	)	)	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
three	CD	three	three	three	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
incidence	NN	incidence	incidence	incid	N	O
in	IN	in	in	in	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
versus	NN	versus	versus	versu	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
from	IN	from	from	from	N	O
Three	NNP	three	three	three	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
Trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
Adults	NNP	adults	adult	adult	N	O
with	IN	with	with	with	N	O
Chronic	NNP	chronic	chronic	chronic	N	O
Immune	NNP	immune	immune	immun	N	O
(	(	(	(	(	N	O
Idiopathic	NNP	idiopathic	idiopathic	idiopath	N	O
)	)	)	)	)	N	O
Thrombocytopenia	NNP	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
50	CD	50	50	50	N	O
mg	NN	mg	mg	mg	N	O
n	RB	n	n	n	N	O
241	CD	241	241	241	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
n	$	n	n	n	N	O
128	CD	128	128	128	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
9	CD	9	9	9	N	O
3	CD	3	3	3	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
9	CD	9	9	9	N	O
7	CD	7	7	7	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
7	CD	7	7	7	N	O
6	CD	6	6	6	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
6	CD	6	6	6	N	O
1	CD	1	1	1	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
5	CD	5	5	5	N	O
3	CD	3	3	3	N	O

Myalgia	NNP	myalgia	myalgia	myalgia	Y	B-AdverseReaction
5	CD	5	5	5	N	O
2	CD	2	2	2	N	O

Urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
5	CD	5	5	5	N	O
3	CD	3	3	3	N	O

Oropharyngeal	NNP	oropharyngeal	oropharyngeal	oropharyng	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
4	CD	4	4	4	N	O
3	CD	3	3	3	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
AST	$	ast	ast	ast	N	I-AdverseReaction
4	CD	4	4	4	N	O
2	CD	2	2	2	N	O

Pharyngitis	NN	pharyngitis	pharyngitis	pharyng	Y	B-AdverseReaction
4	CD	4	4	4	N	O
2	CD	2	2	2	N	O

Back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
3	CD	3	3	3	N	O
2	CD	2	2	2	N	O

Influenza	NNP	influenza	influenza	influenza	Y	B-AdverseReaction
3	CD	3	3	3	N	O
2	CD	2	2	2	N	O

Paresthesia	NNP	paresthesia	paresthesia	paresthesia	Y	B-AdverseReaction
3	CD	3	3	3	N	O
2	CD	2	2	2	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
3	CD	3	3	3	N	O
2	CD	2	2	2	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
three	CD	three	three	three	N	O
controlled	VBD	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
chronic	NN	chronic	chronic	chronic	N	O
ITP	NNP	itp	itp	itp	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
alopecia	NN	alopecia	alopecia	alopecia	Y	B-AdverseReaction
,	,	,	,	,	N	O
musculoskeletal	JJ	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
blood	NN	blood	blood	blood	N	B-AdverseReaction
alkaline	JJ	alkaline	alkaline	alkalin	N	I-AdverseReaction
phosphatase	NN	phosphatase	phosphatase	phosphatas	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
dry	JJ	dry	dry	dri	N	B-AdverseReaction
mouth	NN	mouth	mouth	mouth	N	I-AdverseReaction
were	VBD	were	were	were	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
no	DT	no	no	no	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Among	IN	among	among	among	N	O

299	CD	299	299	299	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
chronic	JJ	chronic	chronic	chronic	N	O
ITP	NNP	itp	itp	itp	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
single	JJ	single	single	singl	N	O
-	:	-	-	-	N	O
arm	NN	arm	arm	arm	N	O
extension	NN	extension	extension	extens	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
pattern	NN	pattern	pattern	pattern	N	O
similar	JJ	similar	similar	similar	N	O
to	TO	to	to	to	N	O
that	DT	that	that	that	N	O
seen	VBN	seen	seen	seen	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
presents	VBZ	presents	present	present	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
experienced	VBN	experienced	experienced	experienc	N	O
by	IN	by	by	by	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
)	)	)	)	)	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
extension	NN	extension	extension	extens	N	O
trial	NN	trial	trial	trial	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
.	.	.	.	.	N	O

Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
from	IN	from	from	from	N	O
Extension	NNP	extension	extension	extens	N	O
Trial	NNP	trial	trial	trial	N	O
in	IN	in	in	in	N	O
Adults	NNP	adults	adult	adult	N	O
with	IN	with	with	with	N	O
Chronic	NNP	chronic	chronic	chronic	N	O
Immune	NNP	immune	immune	immun	N	O
(	(	(	(	(	N	O
Idiopathic	NNP	idiopathic	idiopathic	idiopath	N	O
)	)	)	)	)	N	O
Thrombocytopenia	NNP	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
50	CD	50	50	50	N	O
mg	NN	mg	mg	mg	N	O
n	RB	n	n	n	N	O
299	CD	299	299	299	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Headache	$	headache	headache	headach	Y	B-AdverseReaction
10	CD	10	10	10	N	O

Hyperbilirubinemia	$	hyperbilirubinemia	hyperbilirubinemia	hyperbilirubinemia	Y	B-AdverseReaction
6	CD	6	6	6	N	O

ALT	NNP	alt	alt	alt	N	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
6	CD	6	6	6	N	O

Cataract	NN	cataract	cataract	cataract	Y	B-AdverseReaction
5	CD	5	5	5	N	O

AST	NNP	ast	ast	ast	N	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
4	CD	4	4	4	N	O

Fatigue	CD	fatigue	fatigue	fatigu	Y	B-AdverseReaction
4	CD	4	4	4	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
4	CD	4	4	4	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
three	CD	three	three	three	N	O
controlled	VBD	controlled	controlled	control	N	O
chronic	JJ	chronic	chronic	chronic	N	O
ITP	NNP	itp	itp	itp	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
serum	NN	serum	serum	serum	N	B-AdverseReaction
liver	RB	liver	liver	liver	N	I-AdverseReaction
test	NN	test	test	test	N	I-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
(	(	(	(	(	N	O
predominantly	RB	predominantly	predominantly	predominantli	N	O
Grade	VBZ	grade	grade	grade	N	B-Severity
2	CD	2	2	2	N	I-Severity
or	CC	or	or	or	N	O
less	JJR	less	le	less	N	O
in	IN	in	in	in	N	O
severity	NN	severity	severity	sever	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
11%	CD	11%	11%	11%	N	O
and	CC	and	and	and	N	O
7%	CD	7%	7%	7%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
and	CC	and	and	and	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Four	CD	four	four	four	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
and	CC	and	and	and	N	O
three	CD	three	three	three	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
hepatobiliary	JJ	hepatobiliary	hepatobiliary	hepatobiliari	N	B-AdverseReaction
laboratory	NN	laboratory	laboratory	laboratori	N	I-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
.	.	.	.	.	N	O

Seven	CD	seven	seven	seven	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
controlled	JJ	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
hepatobiliary	JJ	hepatobiliary	hepatobiliary	hepatobiliari	N	B-AdverseReaction
laboratory	NN	laboratory	laboratory	laboratori	N	I-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
were	VBD	were	were	were	N	O
re	JJ	re	re	re	N	O
-	:	-	-	-	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
extension	NN	extension	extension	extens	N	O
trial	NN	trial	trial	trial	N	O
.	.	.	.	.	N	O

Six	CD	six	six	six	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
again	RB	again	again	again	N	O
experienced	VBD	experienced	experienced	experienc	N	O
liver	JJ	liver	liver	liver	N	B-AdverseReaction
test	NN	test	test	test	N	I-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
(	(	(	(	(	N	O
predominantly	RB	predominantly	predominantly	predominantli	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
1	CD	1	1	1	N	I-Severity
)	)	)	)	)	N	O
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
in	IN	in	in	in	N	O
one	CD	one	one	one	N	O
patient	NN	patient	patient	patient	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
extension	NN	extension	extension	extens	N	O
chronic	JJ	chronic	chronic	chronic	N	O
ITP	NNP	itp	itp	itp	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
one	CD	one	one	one	N	O
additional	JJ	additional	additional	addit	N	O
patient	NN	patient	patient	patient	N	O
had	VBD	had	had	had	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
liver	VB	liver	liver	liver	N	B-AdverseReaction
test	NN	test	test	test	N	I-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
(	(	(	(	(	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
Grade	VB	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O

a	DT	a	a	a	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
of	IN	of	of	of	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
chronic	JJ	chronic	chronic	chronic	N	O
liver	NN	liver	liver	liver	N	O
diseaseand	NN	diseaseand	diseaseand	diseaseand	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	O
not	RB	not	not	not	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
ITP	NNP	itp	itp	itp	N	O
,	,	,	,	,	N	O
six	CD	six	six	six	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
and	CC	and	and	and	N	O
one	CD	one	one	one	N	O
patient	NN	patient	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
group	NN	group	group	group	N	O
developed	VBD	developed	developed	develop	N	O
portal	JJ	portal	portal	portal	N	B-AdverseReaction
vein	NN	vein	vein	vein	N	I-AdverseReaction
thromboses	VBZ	thromboses	thromboses	thrombos	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Pediatric	JJ	pediatric	pediatric	pediatr	N	O
Patients	NNS	patients	patient	patient	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
described	VBD	described	described	describ	N	O
below	IN	below	below	below	N	O
reflect	JJ	reflect	reflect	reflect	N	O
median	JJ	median	median	median	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
of	IN	of	of	of	N	O
91	CD	91	91	91	N	O
days	NNS	days	day	day	N	O
for	IN	for	for	for	N	O
82	CD	82	82	82	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
aged	VBN	aged	aged	age	N	O
6	CD	6	6	6	N	O
to	TO	to	to	to	N	O
17	CD	17	17	17	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
chronic	JJ	chronic	chronic	chronic	N	O
ITP	NNP	itp	itp	itp	N	O
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
whom	WP	whom	whom	whom	N	O
52%	CD	52%	52%	52%	N	O
were	VBD	were	were	were	N	O
female	JJ	female	female	femal	N	O
,	,	,	,	,	N	O
across	IN	across	across	across	N	O
the	DT	the	the	the	N	O
randomized	JJ	randomized	randomized	random	N	O
phase	NN	phase	phase	phase	N	O
of	IN	of	of	of	N	O
two	CD	two	two	two	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
6	CD	6	6	6	N	O
presents	VBZ	presents	present	present	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
experienced	VBN	experienced	experienced	experienc	N	O
by	IN	by	by	by	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
6	CD	6	6	6	N	O
years	NNS	years	year	year	N	O
and	CC	and	and	and	N	O
older	JJR	older	older	older	N	O
receiving	VBG	receiving	receiving	receiv	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
)	)	)	)	)	N	O
across	IN	across	across	across	N	O
the	DT	the	the	the	N	O
two	CD	two	two	two	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
incidence	NN	incidence	incidence	incid	N	O
for	IN	for	for	for	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
versus	NN	versus	versus	versu	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
6	CD	6	6	6	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
Higher	JJR	higher	higher	higher	N	O
Incidence	NN	incidence	incidence	incid	N	O
for	IN	for	for	for	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
versus	NN	versus	versus	versu	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
from	IN	from	from	from	N	O
Two	CD	two	two	two	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
Trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
Pediatric	NNP	pediatric	pediatric	pediatr	N	O
Patients	NNPS	patients	patient	patient	N	O
6	CD	6	6	6	N	O
Years	NNS	years	year	year	N	O
and	CC	and	and	and	N	O
Older	JJR	older	older	older	N	O
with	IN	with	with	with	N	O
Chronic	NNP	chronic	chronic	chronic	N	O
Immune	NNP	immune	immune	immun	N	O
(	(	(	(	(	N	O
Idiopathic	NNP	idiopathic	idiopathic	idiopath	N	O
)	)	)	)	)	N	O
Thrombocytopenia	NNP	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	O

PROMACTA	NNP	promacta	promacta	promacta	N	O
Placebo	NNP	placebo	placebo	placebo	N	O

n	RB	n	n	n	N	O
82	CD	82	82	82	N	O
n	NNS	n	n	n	N	O
40	CD	40	40	40	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
16	CD	16	16	16	N	O
5	CD	5	5	5	N	O

Nasopharyngitis	RB	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
12	CD	12	12	12	N	O
5	CD	5	5	5	N	O

Rhinitis	RB	rhinitis	rhinitis	rhiniti	Y	B-AdverseReaction
11	CD	11	11	11	N	O
8	CD	8	8	8	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
9	CD	9	9	9	N	O
5	CD	5	5	5	N	O

Cough	NNP	cough	cough	cough	Y	B-AdverseReaction
9	CD	9	9	9	N	O
0	CD	0	0	0	N	O

Oropharyngeal	NNP	oropharyngeal	oropharyngeal	oropharyng	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
9	CD	9	9	9	N	O
3	CD	3	3	3	N	O

Toothache	NNP	toothache	toothache	toothach	Y	B-AdverseReaction
6	CD	6	6	6	N	O
0	CD	0	0	0	N	O

AST	NNP	ast	ast	ast	N	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
5	CD	5	5	5	N	O
0	CD	0	0	0	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
5	CD	5	5	5	N	O
3	CD	3	3	3	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
5	CD	5	5	5	N	O
3	CD	3	3	3	N	O

ALT	NNP	alt	alt	alt	N	B-AdverseReaction
increaseda	VBZ	increaseda	increaseda	increaseda	N	I-AdverseReaction
6	CD	6	6	6	N	O
0	CD	0	0	0	N	O

Vitamin	NNP	vitamin	vitamin	vitamin	N	B-AdverseReaction
D	NNP	d	d	d	N	I-AdverseReaction
deficiency	NN	deficiency	deficiency	defici	N	I-AdverseReaction
4	CD	4	4	4	N	O
0	CD	0	0	0	N	O

a	DT	a	a	a	N	O
Includes	NNP	includes	includes	includ	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
or	CC	or	or	or	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
3	CD	3	3	3	N	O
x	JJ	x	x	x	N	O
ULN	NNP	uln	uln	uln	N	O
.	.	.	.	.	N	O

Chronic	NNP	chronic	chronic	chronic	N	O
Hepatitis	NNP	hepatitis	hepatitis	hepat	Y	O
C	NNP	c	c	c	N	O
-	:	-	-	-	N	O
associated	VBN	associated	associated	associ	N	O
Thrombocytopenia	NNP	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	O
:	:	:	:	:	N	O
In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
two	CD	two	two	two	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
955	CD	955	955	955	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
chronic	JJ	chronic	chronic	chronic	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
C	NNP	c	c	c	N	O
-	:	-	-	-	N	O
associated	VBN	associated	associated	associ	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	O
received	VBD	received	received	receiv	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
7	CD	7	7	7	N	O
presents	VBZ	presents	present	present	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
experienced	VBN	experienced	experienced	experienc	N	O
by	IN	by	by	by	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	NN	table	table	tabl	N	O

7	CD	7	7	7	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
and	CC	and	and	and	N	O
Greater	NNP	greater	greater	greater	N	O
than	IN	than	than	than	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
from	IN	from	from	from	N	O
Two	CD	two	two	two	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
Trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
Adults	NNP	adults	adult	adult	N	O
with	IN	with	with	with	N	O
Chronic	NNP	chronic	chronic	chronic	N	O
Hepatitis	NNP	hepatitis	hepatitis	hepat	Y	O
C	NNP	c	c	c	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
Peginterferon	NNP	peginterferon	peginterferon	peginterferon	N	O
Ribavirin	NNP	ribavirin	ribavirin	ribavirin	N	O
n	RB	n	n	n	N	O
955	CD	955	955	955	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Peginterferon	NNP	peginterferon	peginterferon	peginterferon	N	O
Ribavirin	NNP	ribavirin	ribavirin	ribavirin	N	O
n	RB	n	n	n	N	O
484	CD	484	484	484	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Anemia	NNP	anemia	anemia	anemia	Y	B-AdverseReaction
40	CD	40	40	40	N	O
35	CD	35	35	35	N	O

Pyrexia	NNP	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
30	CD	30	30	30	N	O
24	CD	24	24	24	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
28	CD	28	28	28	N	O
23	CD	23	23	23	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
21	CD	21	21	21	N	O
20	CD	20	20	20	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
19	CD	19	19	19	N	O
14	CD	14	14	14	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
19	CD	19	19	19	N	O
11	CD	11	11	11	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
18	CD	18	18	18	N	O
14	CD	14	14	14	N	O

Influenza	NNP	influenza	influenza	influenza	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
like	IN	like	like	like	N	I-AdverseReaction
illness	NN	illness	illness	ill	N	I-AdverseReaction
18	CD	18	18	18	N	O
16	CD	16	16	16	N	O

Asthenia	NNP	asthenia	asthenia	asthenia	Y	B-AdverseReaction
16	CD	16	16	16	N	O
13	CD	13	13	13	N	O

Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
16	CD	16	16	16	N	O
15	CD	15	15	15	N	O

Cough	NNP	cough	cough	cough	Y	B-AdverseReaction
15	CD	15	15	15	N	O
12	CD	12	12	12	N	O

Pruritus	NNP	pruritus	pruritus	pruritu	Y	B-AdverseReaction
15	CD	15	15	15	N	O
13	CD	13	13	13	N	O

Chills	NNS	chills	chill	chill	Y	B-AdverseReaction
14	CD	14	14	14	N	O
9	CD	9	9	9	N	O

Myalgia	NNP	myalgia	myalgia	myalgia	Y	B-AdverseReaction
12	CD	12	12	12	N	O
10	CD	10	10	10	N	O

Alopecia	NNP	alopecia	alopecia	alopecia	Y	B-AdverseReaction
10	CD	10	10	10	N	O
6	CD	6	6	6	N	O

Peripheral	NNP	peripheral	peripheral	peripher	N	B-AdverseReaction
edema	VBD	edema	edema	edema	Y	I-AdverseReaction
10	CD	10	10	10	N	O
5	CD	5	5	5	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
two	CD	two	two	two	N	O
controlled	VBD	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
chronic	JJ	chronic	chronic	chronic	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
C	NNP	c	c	c	N	O
,	,	,	,	,	N	O
hyperbilirubinemia	NN	hyperbilirubinemia	hyperbilirubinemia	hyperbilirubinemia	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
8%	CD	8%	8%	8%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
3%	CD	3%	3%	3%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Total	JJ	total	total	total	N	B-AdverseReaction
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	I-AdverseReaction
greater	JJR	greater	greater	greater	N	I-AdverseReaction
than	IN	than	than	than	N	I-AdverseReaction
or	CC	or	or	or	N	I-AdverseReaction
equal	JJ	equal	equal	equal	N	I-AdverseReaction
to	TO	to	to	to	N	I-AdverseReaction
1.5	CD	1.5	1.5	1.5	N	I-AdverseReaction
x	NNS	x	x	x	N	I-AdverseReaction
ULN	NNP	uln	uln	uln	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
76%	CD	76%	76%	76%	N	O
and	CC	and	and	and	N	O
50%	CD	50%	50%	50%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
and	CC	and	and	and	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

ALT	NNP	alt	alt	alt	N	B-AdverseReaction
or	CC	or	or	or	N	O
AST	NNP	ast	ast	ast	N	B-AdverseReaction
greater	JJR	greater	greater	greater	N	I-AdverseReaction
than	IN	than	than	than	N	I-AdverseReaction
or	CC	or	or	or	N	I-AdverseReaction
equal	JJ	equal	equal	equal	N	I-AdverseReaction
to	TO	to	to	to	N	I-AdverseReaction
3	CD	3	3	3	N	I-AdverseReaction
x	NNS	x	x	x	N	I-AdverseReaction
ULN	NNP	uln	uln	uln	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
34%	CD	34%	34%	34%	N	O
and	CC	and	and	and	N	O
38%	CD	38%	38%	38%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
and	CC	and	and	and	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Severe	JJ	severe	severe	sever	N	O

Aplastic	JJ	aplastic	aplastic	aplast	N	O
Anemia	NN	anemia	anemia	anemia	Y	O
:	:	:	:	:	N	O
In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
single	JJ	single	single	singl	N	O
-	:	-	-	-	N	O
arm	NN	arm	arm	arm	N	O
,	,	,	,	,	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
43	CD	43	43	43	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
aplastic	JJ	aplastic	aplastic	aplast	N	O
anemia	NN	anemia	anemia	anemia	Y	O
received	VBD	received	received	receiv	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
.	.	.	.	.	N	O

Eleven	JJ	eleven	eleven	eleven	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
26%	CD	26%	26%	26%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
for	IN	for	for	for	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
and	CC	and	and	and	N	O
7	CD	7	7	7	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
16%	CD	16%	16%	16%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
treated	VBN	treated	treated	treat	N	O
for	IN	for	for	for	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
1	CD	1	1	1	N	O
year	NN	year	year	year	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
nausea	JJ	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
8	CD	8	8	8	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
from	IN	from	from	from	N	O
One	CD	one	one	one	N	O
Open	NNP	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
Trial	NNP	trial	trial	trial	N	O
in	IN	in	in	in	N	O
Adults	NNP	adults	adult	adult	N	O
with	IN	with	with	with	N	O
Severe	NNP	severe	severe	sever	N	O
Aplastic	NNP	aplastic	aplastic	aplast	N	O
Anemia	NNP	anemia	anemia	anemia	Y	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
43	CD	43	43	43	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
33	CD	33	33	33	N	O

Fatigue	CD	fatigue	fatigue	fatigu	Y	B-AdverseReaction
28	CD	28	28	28	N	O

Cough	IN	cough	cough	cough	Y	B-AdverseReaction
23	CD	23	23	23	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
21	CD	21	21	21	N	O

Headache	$	headache	headache	headach	Y	B-AdverseReaction
21	CD	21	21	21	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
19	CD	19	19	19	N	O

Dyspnea	NNP	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
14	CD	14	14	14	N	O

Pyrexia	$	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
14	CD	14	14	14	N	O

Dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
14	CD	14	14	14	N	O

Oropharyngeal	NNP	oropharyngeal	oropharyngeal	oropharyng	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
14	CD	14	14	14	N	O

Febrile	NNP	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	VBZ	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
14	CD	14	14	14	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
12	CD	12	12	12	N	O

Ecchymosis	NN	ecchymosis	ecchymosis	ecchymosi	Y	B-AdverseReaction
12	CD	12	12	12	N	O

Muscle	NNP	muscle	muscle	muscl	N	B-AdverseReaction
spasms	VBD	spasms	spasm	spasm	Y	I-AdverseReaction
12	CD	12	12	12	N	O

Transaminases	NNS	transaminases	transaminase	transaminas	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
12	CD	12	12	12	N	O

Arthralgia	$	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
12	CD	12	12	12	N	O

Rhinorrhea	NNP	rhinorrhea	rhinorrhea	rhinorrhea	Y	B-AdverseReaction
12	CD	12	12	12	N	O

In	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
bone	VBN	bone	bone	bone	N	O
marrow	NN	marrow	marrow	marrow	N	O
aspirates	NNS	aspirates	aspirate	aspir	N	O
evaluated	VBD	evaluated	evaluated	evalu	N	O
for	IN	for	for	for	N	O
cytogenetic	JJ	cytogenetic	cytogenetic	cytogenet	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
.	.	.	.	.	N	O

Eight	CD	eight	eight	eight	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
new	JJ	new	new	new	N	O
cytogenetic	JJ	cytogenetic	cytogenetic	cytogenet	N	B-AdverseReaction
abnormality	NN	abnormality	abnormality	abnorm	N	I-AdverseReaction
reported	VBN	reported	reported	report	N	O
on	IN	on	on	on	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
5	CD	5	5	5	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
complex	JJ	complex	complex	complex	N	O
changes	NNS	changes	change	chang	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
chromosome	NN	chromosome	chromosome	chromosom	N	I-AdverseReaction
7	CD	7	7	7	N	I-AdverseReaction
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O

Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
approval	NN	approval	approval	approv	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
the	DT	the	the	the	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
Thrombotic	NNP	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
microangiopathy	NN	microangiopathy	microangiopathy	microangiopathi	Y	I-AdverseReaction
with	IN	with	with	with	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
.	.	.	.	.	N	O
\n\n	CC	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NNP	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
RISK	NN	risk	risk	risk	N	B-Factor
FOR	NNP	for	for	for	N	O
HEPATIC	NNP	hepatic	hepatic	hepat	N	B-AdverseReaction
DECOMPENSATION	NNP	decompensation	decompensation	decompens	N	I-AdverseReaction
IN	NNP	in	in	in	N	O
PATIENTS	NNP	patients	patient	patient	N	O
WITH	NNP	with	with	with	N	O
CHRONIC	NNP	chronic	chronic	chronic	N	O
HEPATITIS	NNP	hepatitis	hepatitis	hepat	Y	O
C	NNP	c	c	c	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
RISK	NN	risk	risk	risk	N	B-Factor
FOR	NNP	for	for	for	N	O
HEPATIC	NNP	hepatic	hepatic	hepat	N	B-AdverseReaction
DECOMPENSATION	NNP	decompensation	decompensation	decompens	N	I-AdverseReaction
IN	NNP	in	in	in	N	O
PATIENTS	NNP	patients	patient	patient	N	O
WITH	NNP	with	with	with	N	O
CHRONIC	NNP	chronic	chronic	chronic	N	O
HEPATITIS	NNP	hepatitis	hepatitis	hepat	Y	O
C	NNP	c	c	c	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
chronic	JJ	chronic	chronic	chronic	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
C	NNP	c	c	c	N	O
,	,	,	,	,	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
(	(	(	(	(	N	O
r	NN	r	r	r	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
interferon	NN	interferon	interferon	interferon	N	O
and	CC	and	and	and	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
decompensation	NN	decompensation	decompensation	decompens	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
RISK	NN	risk	risk	risk	N	B-Factor
FOR	NNP	for	for	for	N	O
HEPATIC	NNP	hepatic	hepatic	hepat	N	B-AdverseReaction
DECOMPENSATION	NNP	decompensation	decompensation	decompens	N	I-AdverseReaction
IN	NNP	in	in	in	N	O
PATIENTS	NNP	patients	patient	patient	N	O
WITH	NNP	with	with	with	N	O
CHRONIC	NNP	chronic	chronic	chronic	N	O
HEPATITIS	NNP	hepatitis	hepatitis	hepat	Y	O
C	NNP	c	c	c	N	O
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
chronic	JJ	chronic	chronic	chronic	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
C	NNP	c	c	c	N	O
,	,	,	,	,	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
interferon	NN	interferon	interferon	interferon	N	O
and	CC	and	and	and	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
decompensation	NN	decompensation	decompensation	decompens	N	I-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
\n	VBD	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
liver	WRB	liver	liver	liver	N	O
function	NN	function	function	function	N	O
before	IN	before	before	befor	N	O
and	CC	and	and	and	N	O
during	IN	during	during	dure	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Thrombotic	JJ	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
Thromboembolic	NNP	thromboembolic	thromboembolic	thromboembol	N	B-AdverseReaction
Complications	NNPS	complications	complication	complic	N	I-AdverseReaction
:	:	:	:	:	N	O
Portal	JJ	portal	portal	portal	N	B-AdverseReaction
vein	NN	vein	vein	vein	N	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
chronic	JJ	chronic	chronic	chronic	N	O
liver	NN	liver	liver	liver	N	O
disease	NN	disease	disease	diseas	N	O
receiving	VBG	receiving	receiving	receiv	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
platelet	NN	platelet	platelet	platelet	N	O
counts	VBZ	counts	count	count	N	O
regularly	RB	regularly	regularly	regularli	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Hepatic	JJ	hepatic	hepatic	hepat	N	O

Decompensation	NN	decompensation	decompensation	decompens	N	O
in	IN	in	in	in	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Chronic	NNP	chronic	chronic	chronic	N	O
Hepatitis	NNP	hepatitis	hepatitis	hepat	Y	O
C	NNP	c	c	c	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
chronic	JJ	chronic	chronic	chronic	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
C	NNP	c	c	c	N	O
,	,	,	,	,	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
interferon	NN	interferon	interferon	interferon	N	O
and	CC	and	and	and	N	O
ribavirin	NN	ribavirin	ribavirin	ribavirin	N	O
may	MD	may	may	may	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
decompensation	NN	decompensation	decompensation	decompens	N	I-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
two	CD	two	two	two	N	O
controlled	VBD	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
chronic	JJ	chronic	chronic	chronic	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
C	NNP	c	c	c	N	O
and	CC	and	and	and	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	O
,	,	,	,	,	N	O
ascites	NNS	ascites	ascites	ascit	Y	B-AdverseReaction
and	CC	and	and	and	N	O
encephalopathy	VB	encephalopathy	encephalopathy	encephalopathi	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
arm	NN	arm	arm	arm	N	O
receiving	NN	receiving	receiving	receiv	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
plus	CC	plus	plus	plu	N	O
antivirals	NNS	antivirals	antiviral	antivir	N	O
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O
than	IN	than	than	than	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
plus	CC	plus	plus	plu	N	O
antivirals	NNS	antivirals	antiviral	antivir	N	O
arm	NN	arm	arm	arm	N	O
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
low	JJ	low	low	low	N	O
albumin	NN	albumin	albumin	albumin	Y	O
levels	NNS	levels	level	level	N	O
(	(	(	(	(	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
3.5	CD	3.5	3.5	3.5	N	O
g	JJ	g	g	g	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
Model	NNP	model	model	model	N	O
for	IN	for	for	for	N	O
End	NNP	end	end	end	N	O
-	:	-	-	-	N	O
Stage	NN	stage	stage	stage	N	O
Liver	NNP	liver	liver	liver	N	O
Disease	NNP	disease	disease	diseas	N	O
(	(	(	(	(	N	O
MELD	NNP	meld	meld	meld	N	O
)	)	)	)	)	N	O
score	NN	score	score	score	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
10	CD	10	10	10	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
greater	JJR	greater	greater	greater	N	O
risk	NN	risk	risk	risk	N	B-Factor
for	IN	for	for	for	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
decompensation	NN	decompensation	decompensation	decompens	N	I-AdverseReaction
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
arm	NN	arm	arm	arm	N	O
receiving	NN	receiving	receiving	receiv	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
plus	CC	plus	plus	plu	N	O
antivirals	NNS	antivirals	antiviral	antivir	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
if	IN	if	if	if	N	O
antiviral	JJ	antiviral	antiviral	antivir	N	O
therapy	NN	therapy	therapy	therapi	N	O
is	VBZ	is	is	is	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	O

PROMACTA	NNP	promacta	promacta	promacta	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
liver	JJ	liver	liver	liver	N	B-AdverseReaction
enzyme	JJ	enzyme	enzyme	enzym	N	I-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Measure	NN	measure	measure	measur	N	O
serum	NN	serum	serum	serum	N	O
ALT	NNP	alt	alt	alt	N	O
,	,	,	,	,	N	O
AST	NNP	ast	ast	ast	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
bilirubin	RB	bilirubin	bilirubin	bilirubin	Y	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
,	,	,	,	,	N	O
every	DT	every	every	everi	N	O
2	CD	2	2	2	N	O
weeks	NNS	weeks	week	week	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
dose	JJ	dose	dose	dose	N	O
adjustment	NN	adjustment	adjustment	adjust	N	O
phase	NN	phase	phase	phase	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
monthly	RB	monthly	monthly	monthli	N	O
following	VBG	following	following	follow	N	O
establishment	NN	establishment	establishment	establish	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
stable	JJ	stable	stable	stabl	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

PROMACTA	NNP	promacta	promacta	promacta	N	O
inhibits	VBZ	inhibits	inhibits	inhibit	N	O
UDP	NNP	udp	udp	udp	N	O
-	:	-	-	-	N	O
glucuronosyltransferase	NN	glucuronosyltransferase	glucuronosyltransferase	glucuronosyltransferas	N	O
(	(	(	(	(	N	O
UGT	NNP	ugt	ugt	ugt	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
A1	NNP	a1	a1	a1	N	O
and	CC	and	and	and	N	O
organic	JJ	organic	organic	organ	N	O
anion	NN	anion	anion	anion	N	O
-	:	-	-	-	N	O
transporting	NN	transporting	transporting	transport	N	O
polypeptide	NN	polypeptide	polypeptide	polypeptid	N	O
(	(	(	(	(	N	O
OATP	NNP	oatp	oatp	oatp	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
B1	NNP	b1	b1	b1	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	B-Factor
lead	VB	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
indirect	JJ	indirect	indirect	indirect	N	B-AdverseReaction
hyperbilirubinemia	NN	hyperbilirubinemia	hyperbilirubinemia	hyperbilirubinemia	Y	I-AdverseReaction
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
bilirubin	VBN	bilirubin	bilirubin	bilirubin	Y	O
is	VBZ	is	is	is	N	O
elevated	VBN	elevated	elevated	elev	N	O
,	,	,	,	,	N	O
perform	VB	perform	perform	perform	N	O
fractionation	NN	fractionation	fractionation	fraction	N	O
.	.	.	.	.	N	O

Evaluate	NNP	evaluate	evaluate	evalu	N	O
abnormal	JJ	abnormal	abnormal	abnorm	N	O
serum	NN	serum	serum	serum	N	O
liver	NN	liver	liver	liver	N	O
tests	NNS	tests	test	test	N	O
with	IN	with	with	with	N	O
repeat	NN	repeat	repeat	repeat	N	O
testing	VBG	testing	testing	test	N	O
within	IN	within	within	within	N	O
3	CD	3	3	3	N	O
to	TO	to	to	to	N	O
5	CD	5	5	5	N	O
days	NNS	days	day	day	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
the	DT	the	the	the	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
are	VBP	are	are	are	N	O
confirmed	VBN	confirmed	confirmed	confirm	N	O
,	,	,	,	,	N	O
monitor	NN	monitor	monitor	monitor	N	O
serum	NN	serum	serum	serum	N	O
liver	NN	liver	liver	liver	N	O
tests	NNS	tests	test	test	N	O
weekly	RB	weekly	weekly	weekli	N	O
until	IN	until	until	until	N	O
resolved	VBN	resolved	resolved	resolv	N	O
or	CC	or	or	or	N	O
stabilized	VBN	stabilized	stabilized	stabil	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
if	IN	if	if	if	N	O
ALT	NNP	alt	alt	alt	N	O
levels	NNS	levels	level	level	N	O
increase	NN	increase	increase	increas	N	O
to	TO	to	to	to	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
x	NNS	x	x	x	N	O
ULN	NNP	uln	uln	uln	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
normal	JJ	normal	normal	normal	N	O
liver	JJ	liver	liver	liver	N	O
function	NN	function	function	function	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
x	NNS	x	x	x	N	O
baseline	NN	baseline	baseline	baselin	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
pre	JJ	pre	pre	pre	N	O
-	:	-	-	-	N	O
treatment	NN	treatment	treatment	treatment	N	O
elevations	NNS	elevations	elevation	elev	N	O
in	IN	in	in	in	N	O
transaminases	NNS	transaminases	transaminase	transaminas	Y	O
and	CC	and	and	and	N	O
are	VBP	are	are	are	N	O
:	:	:	:	:	N	O

progressively	RB	progressively	progressively	progress	N	O
increasing	VBG	increasing	increasing	increas	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O

persistent	NN	persistent	persistent	persist	N	O
for	IN	for	for	for	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
4	CD	4	4	4	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O

accompanied	VBN	accompanied	accompanied	accompani	N	O
by	IN	by	by	by	N	O
increased	JJ	increased	increased	increas	N	O
direct	JJ	direct	direct	direct	N	O
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O

accompanied	VBN	accompanied	accompanied	accompani	N	O
by	IN	by	by	by	N	O
clinical	JJ	clinical	clinical	clinic	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
liver	JJ	liver	liver	liver	N	O
injury	NN	injury	injury	injuri	Y	O
or	CC	or	or	or	N	O
evidence	NN	evidence	evidence	evid	N	O
for	IN	for	for	for	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
decompensation	NN	decompensation	decompensation	decompens	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
benefit	NN	benefit	benefit	benefit	N	O
for	IN	for	for	for	N	O
reinitiating	VBG	reinitiating	reinitiating	reiniti	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
is	VBZ	is	is	is	N	O
considered	VBN	considered	considered	consid	N	O
to	TO	to	to	to	N	O
outweigh	VB	outweigh	outweigh	outweigh	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	O
,	,	,	,	,	N	O
then	RB	then	then	then	N	O
consider	VB	consider	consider	consid	N	O
cautiously	RB	cautiously	cautiously	cautious	N	O
reintroducing	VBG	reintroducing	reintroducing	reintroduc	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
and	CC	and	and	and	N	O
measure	NN	measure	measure	measur	N	O
serum	NN	serum	serum	serum	N	O
liver	NN	liver	liver	liver	N	O
tests	NNS	tests	test	test	N	O
weekly	VBP	weekly	weekly	weekli	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
dose	JJ	dose	dose	dose	N	O
adjustment	NN	adjustment	adjustment	adjust	N	O
phase	NN	phase	phase	phase	N	O
.	.	.	.	.	N	O

Hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
reoccur	VB	reoccur	reoccur	reoccur	N	O
if	IN	if	if	if	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
is	VBZ	is	is	is	N	O
reinitiated	VBN	reinitiated	reinitiated	reiniti	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
liver	JJ	liver	liver	liver	N	O
test	NN	test	test	test	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
persist	VBP	persist	persist	persist	N	O
,	,	,	,	,	N	O
worsen	VBP	worsen	worsen	worsen	N	O
or	CC	or	or	or	N	O
recur	VBP	recur	recur	recur	N	O
,	,	,	,	,	N	O
then	RB	then	then	then	N	O
permanently	RB	permanently	permanently	perman	N	O
discontinue	VBP	discontinue	discontinue	discontinu	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O

Thrombotic	JJ	thrombotic	thrombotic	thrombot	N	O
Thromboembolic	NNP	thromboembolic	thromboembolic	thromboembol	N	O
Complications	NNP	complications	complication	complic	N	O

In	IN	in	in	in	N	O
two	CD	two	two	two	N	O
controlled	VBD	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
chronic	JJ	chronic	chronic	chronic	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
C	NNP	c	c	c	N	O
and	CC	and	and	and	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	O
,	,	,	,	,	N	O
3%	CD	3%	3%	3%	N	O
(	(	(	(	(	N	O
31	CD	31	31	31	N	O
955	CD	955	955	955	N	O
)	)	)	)	)	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
experienced	VBD	experienced	experienced	experienc	N	O
a	DT	a	a	a	N	O
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
event	NN	event	event	event	N	I-AdverseReaction
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
1%	CD	1%	1%	1%	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
484	CD	484	484	484	N	O
)	)	)	)	)	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
events	NNS	events	event	event	N	I-AdverseReaction
were	VBD	were	were	were	N	O
of	IN	of	of	of	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
portal	JJ	portal	portal	portal	N	I-AdverseReaction
venous	JJ	venous	venous	venou	N	I-AdverseReaction
system	NN	system	system	system	N	I-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
versus	NN	versus	versus	versu	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1%	CD	1%	1%	1%	N	O
for	IN	for	for	for	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Thrombotic	JJ	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	B-AdverseReaction
complications	NNS	complications	complication	complic	N	I-AdverseReaction
may	MD	may	may	may	N	B-Factor
result	VB	result	result	result	N	O
from	IN	from	from	from	N	O
increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
platelet	NN	platelet	platelet	platelet	N	I-AdverseReaction
counts	NNS	counts	count	count	N	I-AdverseReaction
with	IN	with	with	with	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
.	.	.	.	.	N	O

Reported	VBN	reported	reported	report	N	O
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	B-AdverseReaction
complications	NNS	complications	complication	complic	N	I-AdverseReaction
included	VBD	included	included	includ	N	O
both	DT	both	both	both	N	O
venous	JJ	venous	venous	venou	N	I-AdverseReaction
and	CC	and	and	and	N	O
arterial	JJ	arterial	arterial	arteri	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
and	CC	and	and	and	N	O
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
at	IN	at	at	at	N	O
low	JJ	low	low	low	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
normal	JJ	normal	normal	normal	N	O
platelet	NN	platelet	platelet	platelet	N	O
counts	NNS	counts	count	count	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
the	DT	the	the	the	N	O
potential	NN	potential	potential	potenti	N	O
for	IN	for	for	for	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
thromboembolism	NN	thromboembolism	thromboembolism	thromboembol	Y	O
when	WRB	when	when	when	N	O
administering	VBG	administering	administering	administ	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
known	VBN	known	known	known	N	O
risk	NN	risk	risk	risk	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
thromboembolism	NN	thromboembolism	thromboembolism	thromboembol	Y	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
Factor	NNP	factor	factor	factor	N	O
V	NNP	v	v	v	N	O
Leiden	NNP	leiden	leiden	leiden	N	O
,	,	,	,	,	N	O
ATIII	NNP	atiii	atiii	atiii	N	O
deficiency	NN	deficiency	deficiency	defici	N	O
,	,	,	,	,	N	O
antiphospholipid	JJ	antiphospholipid	antiphospholipid	antiphospholipid	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
,	,	,	,	,	N	O
chronic	JJ	chronic	chronic	chronic	N	O
liver	NN	liver	liver	liver	N	O
disease	NN	disease	disease	diseas	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

To	TO	to	to	to	N	O
minimize	VB	minimize	minimize	minim	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	O
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	O
complications	NNS	complications	complication	complic	N	O
,	,	,	,	,	N	O
do	VBP	do	do	do	N	O
not	RB	not	not	not	N	O
use	VB	use	use	use	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
attempt	NN	attempt	attempt	attempt	N	O
to	TO	to	to	to	N	O
normalize	VB	normalize	normalize	normal	N	O
platelet	NN	platelet	platelet	platelet	N	O
counts	NNS	counts	count	count	N	O
.	.	.	.	.	N	O

Follow	IN	follow	follow	follow	N	O
the	DT	the	the	the	N	O
dose	JJ	dose	dose	dose	N	O
adjustment	NN	adjustment	adjustment	adjust	N	O
guidelines	NNS	guidelines	guideline	guidelin	N	O
to	TO	to	to	to	N	O
achieve	VB	achieve	achieve	achiev	N	O
and	CC	and	and	and	N	O
maintain	VB	maintain	maintain	maintain	N	O
target	NN	target	target	target	N	O
platelet	NN	platelet	platelet	platelet	N	O
counts	VBZ	counts	count	count	N	O
[	JJ	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
,	,	,	,	,	N	O
2.2	CD	2.2	2.2	2.2	N	O
,	,	,	,	,	N	O
2.3	CD	2.3	2.3	2.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
controlled	JJ	controlled	controlled	control	N	O
trial	NN	trial	trial	trial	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
chronic	JJ	chronic	chronic	chronic	N	O
liver	NN	liver	liver	liver	N	O
disease	NN	disease	disease	diseas	N	O
and	CC	and	and	and	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	O
not	RB	not	not	not	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
ITP	NNP	itp	itp	itp	N	O
undergoing	VBG	undergoing	undergoing	undergo	N	O
elective	JJ	elective	elective	elect	N	O
invasive	JJ	invasive	invasive	invas	N	O
procedures	NNS	procedures	procedure	procedur	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
292	CD	292	292	292	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
increased	VBN	increased	increased	increas	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
75	CD	75	75	75	N	O
mg	NNS	mg	mg	mg	N	O
of	IN	of	of	of	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
once	RB	once	once	onc	N	O
daily	RB	daily	daily	daili	N	O
.	.	.	.	.	N	O

Seven	NNP	seven	seven	seven	N	O
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
complications	NNS	complications	complication	complic	N	I-AdverseReaction
(	(	(	(	(	N	O
six	CD	six	six	six	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
group	NN	group	group	group	N	O
that	WDT	that	that	that	N	O
received	VBD	received	received	receiv	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
and	CC	and	and	and	N	O
three	CD	three	three	three	N	O
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
complications	NNS	complications	complication	complic	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	B-Factor
group	NN	group	group	group	N	O
(	(	(	(	(	N	O
two	CD	two	two	two	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
complications	NNS	complications	complication	complic	N	I-AdverseReaction
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
group	NN	group	group	group	N	O
that	WDT	that	that	that	N	O
received	VBD	received	received	receiv	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
were	VBD	were	were	were	N	O
portal	JJ	portal	portal	portal	N	B-AdverseReaction
vein	JJ	vein	vein	vein	N	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
(	(	(	(	(	N	O
PVT	NNP	pvt	pvt	pvt	N	B-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
PVT	NNP	pvt	pvt	pvt	N	B-AdverseReaction
included	VBD	included	included	includ	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	NN	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
.	.	.	.	.	N	O

Five	CD	five	five	five	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
six	CD	six	six	six	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
group	NN	group	group	group	N	O
that	WDT	that	that	that	N	O
received	VBD	received	received	receiv	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
experienced	VBD	experienced	experienced	experienc	N	O
a	DT	a	a	a	N	O
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	B-AdverseReaction
complication	NN	complication	complication	complic	N	I-AdverseReaction
within	IN	within	within	within	N	O
30	CD	30	30	30	N	O
days	NNS	days	day	day	N	O
of	IN	of	of	of	N	O
completing	VBG	completing	completing	complet	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
platelet	NN	platelet	platelet	platelet	N	O
count	NN	count	count	count	N	O
above	IN	above	above	abov	N	O
200	CD	200	200	200	N	O
x	JJ	x	x	x	N	O
10	CD	10	10	10	N	O
9	CD	9	9	9	N	O
L.	NNP	l.	l.	l.	N	O

The	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
portal	JJ	portal	portal	portal	N	B-AdverseReaction
venous	JJ	venous	venous	venou	N	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
increased	VBN	increased	increased	increas	N	O
in	IN	in	in	in	N	O
thrombocytopenic	JJ	thrombocytopenic	thrombocytopenic	thrombocytopen	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
chronic	JJ	chronic	chronic	chronic	N	O
liver	NN	liver	liver	liver	N	O
disease	NN	disease	disease	diseas	N	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
75	CD	75	75	75	N	O
mg	NNS	mg	mg	mg	N	O
of	IN	of	of	of	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
once	RB	once	once	onc	N	O
daily	RB	daily	daily	daili	N	O
for	IN	for	for	for	N	O
2	CD	2	2	2	N	O
weeks	NNS	weeks	week	week	N	O
in	IN	in	in	in	N	O
preparation	NN	preparation	preparation	prepar	N	O
for	IN	for	for	for	N	O
invasive	JJ	invasive	invasive	invas	N	O
procedures	NNS	procedures	procedure	procedur	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Cataracts	NNS	cataracts	cataract	cataract	Y	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
three	CD	three	three	three	N	O
controlled	VBD	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
adults	NNS	adults	adult	adult	N	O
with	IN	with	with	with	N	O
chronic	JJ	chronic	chronic	chronic	N	O
ITP	NNP	itp	itp	itp	N	O
,	,	,	,	,	N	O
cataracts	VBZ	cataracts	cataract	cataract	Y	B-AdverseReaction
developed	VBN	developed	developed	develop	N	O
or	CC	or	or	or	N	O
worsened	VBN	worsened	worsened	worsen	N	O
in	IN	in	in	in	N	O
15	CD	15	15	15	N	O
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
50	CD	50	50	50	N	O
mg	NN	mg	mg	mg	N	O
of	IN	of	of	of	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
daily	JJ	daily	daily	daili	N	O
and	CC	and	and	and	N	O
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
group	NN	group	group	group	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
extension	NN	extension	extension	extens	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
cataracts	NNS	cataracts	cataract	cataract	Y	B-AdverseReaction
developed	VBD	developed	developed	develop	N	O
or	CC	or	or	or	N	O
worsened	VBN	worsened	worsened	worsen	N	O
in	IN	in	in	in	N	O
4%	CD	4%	4%	4%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
underwent	VBP	underwent	underwent	underw	N	O
ocular	JJ	ocular	ocular	ocular	N	O
examination	NN	examination	examination	examin	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
therapy	VB	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
two	CD	two	two	two	N	O
controlled	VBD	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
chronic	JJ	chronic	chronic	chronic	N	O
hepatitis	NN	hepatitis	hepatitis	hepat	Y	O
C	NNP	c	c	c	N	O
and	CC	and	and	and	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	O
,	,	,	,	,	N	O
cataracts	NNS	cataracts	cataract	cataract	Y	B-AdverseReaction
developed	VBD	developed	developed	develop	N	O
or	CC	or	or	or	N	O
worsened	VBN	worsened	worsened	worsen	N	O
in	IN	in	in	in	N	O
8%	CD	8%	8%	8%	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
and	CC	and	and	and	N	O
5%	CD	5%	5%	5%	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Cataracts	NNS	cataracts	cataract	cataract	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
toxicology	NN	toxicology	toxicology	toxicolog	N	O
studies	NNS	studies	study	studi	N	O
of	IN	of	of	of	N	O
eltrombopag	NN	eltrombopag	eltrombopag	eltrombopag	N	O
in	IN	in	in	in	N	O
rodents	NNS	rodents	rodent	rodent	N	B-Animal
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Nonclinical	JJ	nonclinical	nonclinical	nonclin	N	O
Toxicology	NNP	toxicology	toxicology	toxicolog	N	O
(	(	(	(	(	N	O
13.2	CD	13.2	13.2	13.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Perform	VB	perform	perform	perform	N	O
a	DT	a	a	a	N	O
baseline	NN	baseline	baseline	baselin	N	O
ocular	JJ	ocular	ocular	ocular	N	O
examination	NN	examination	examination	examin	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
and	CC	and	and	and	N	O
,	,	,	,	,	N	O
during	IN	during	during	dure	N	O
therapy	NN	therapy	therapy	therapi	N	O
with	IN	with	with	with	N	O
PROMACTA	NNP	promacta	promacta	promacta	N	O
,	,	,	,	,	N	O
regularly	RB	regularly	regularly	regularli	N	O
monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
cataracts	NNS	cataracts	cataract	cataract	Y	O
.	.	.	.	.	N	O

